Follow us on Twitter
twitter icon@FreshPatents


Insulin Resistance patents

      

This page is updated frequently with new Insulin Resistance-related patent applications.




 Method and system for treating non-alcoholic fatty liver disease patent thumbnailMethod and system for treating non-alcoholic fatty liver disease
A method and system for treating non-alcoholic fatty liver disease (nafld) involves the modulation of the gut microbial of a person suffering from nafld, and in particular the provision of a probiotic therapy configured to reduce liver aminotransferases, total-cholesterol, tnf-α and to improve insulin resistance in nafld patients.. .

 Methods for preventing or treating insulin resistance patent thumbnailMethods for preventing or treating insulin resistance
The invention provides methods of preventing or treating insulin resistance in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (pm) and the total number of amino acid residues (r) wherein 3pm is the largest number that is less than or equal to r+1; and a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (pt) wherein 2a is the largest number that is less than or equal to pt+1, except that when a is 1, pt may also be 1..
East Carolina University


 Improved peptide pharmaceuticals for insulin resistance patent thumbnailImproved peptide pharmaceuticals for insulin resistance
Described herein are methods of syntheses and therapeutic uses of covalently modified peptides and/or proteins. The covalently modified peptides and/or proteins allow for improved pharmaceutical properties of peptide and protein-based therapeutics..
Mederis Diabetes, Llc


 Peptide analogs for treating diseases and disorders patent thumbnailPeptide analogs for treating diseases and disorders
Provided herein are peptides, that in combination with metformin, are effective for the treatment of type i diabetes, type ii diabetes, metabolic syndrome, or obesity, or of appetite suppression, or for mitigating insulin resistance, or for reducing an undesirably high fasting serum glucose level, or for reducing an undesirably high peak serum glucose level, or for reducing an undesirably high peak serum insulin level, or for reducing an undesirably large response to a glucose tolerance test in synergistic combination with metformin. The peptides are selected from sequences seq id no: 11, seq id no: 12, seq id no: 13, seq id no: 14, seq id no: 15, seq id no: 16, seq id no: 17, seq id no: 19, seq id no: 20, seq id no: 21, seq id no: 22, seq id no: 23, and seq id no: 24..
Keybioscience Ag


 Novel activators of glucokinase patent thumbnailNovel activators of glucokinase
The present invention provides for novel compounds of formulas i and ii and pharmaceutically acceptable salts and co-crystals thereof which have glucokinsae activator activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucokinase activator is indicated, including type 1 and 2 diabetes, impaired glucose tolerance, insulin resistance and hyperglycemia.
Metabasis Therapeutics, Inc.


 Uses of mito-ob transgenic mice patent thumbnailUses of mito-ob transgenic mice
The mito-ob obese mouse model overexpresses the mitochondrial protein prohibitin (phb). Mito-ob male mice develop insulin resistance in addition to obesity and they do not develop overt diabetes.
University Of Manitoba


 A novel soluble biomarker for insulin resistance patent thumbnailA novel soluble biomarker for insulin resistance
The present invention relates to a novel soluble biomarker for insulin resistance: 1-methyl nicotinamide (mna). The invention relates to methods of determining the degree of insulin resistance in a patient.
UniversitÄt Leipzig


 Novel compounds as diacylglycerol acyltransferase inhibitors patent thumbnailNovel compounds as diacylglycerol acyltransferase inhibitors
This invention relates to novel compounds which are inhibitors of acyl coenzyme a: diacylglycerol acyltransferase 1 (dgat-1), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination with weight management therapies or other triglyceride lowering therapy for the prevention or treatment of diseases related to dgat-1 dysfunction or where modulation of dgat-1 activity may have therapeutic benefit including but not limited to obesity, obesity related disorders, genetic (type 1, type 5 hyperlipidemia) and acquired forms of hypertriglyceridemia or hyperlipoproteinemia-related disorders, caused by but not limited to lipodystrophy, hypothyroidism, medications (beta blockers, thiazides, estrogen, glucocorticoids, transplant) and other factors (pregnancy, alcohol intake), hyperlipoproteinemia, chylomicronemia, dyslipidemia, non-alcoholic steatohepatitis, diabetes, insulin resistance, metabolic syndrome, cardiovascular outcomes, angina, excess hair growth (including syndromes associated with hirsutism), nephrotic syndrome, fibrosis such as myocardial, renal and liver fibrosis, hepatitis c virus infection and acne or other skin disorders.. .
Glaxosmithkline Llc


 Insulin sensitisers and methods of treatment patent thumbnailInsulin sensitisers and methods of treatment
The present invention relates generally to the field of therapy. The invention particularly relates to insulin sensitisers and methods of regulating glucose homeostasis and to the therapeutic or prophylactic treatment of diseases and associated conditions, in which impaired glucose uptake due to insulin resistance is involved or implicated, such as diabetes, syndrome x, hyperglycaemia, vascular disease and kidney disease.
Naia Metabolic, Inc.


 Compositions and methods for the treatment of diabetes and pre-diabetes patent thumbnailCompositions and methods for the treatment of diabetes and pre-diabetes
The invention relates to the compounds and compositions of formula i, formula ii, formula iii, formula iv, formula v, formula vi or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprises a salt of dipeptidyl peptidase-4 inhibitor and the methods for treating or preventing metabolic syndrome, prediabetes and diabetes may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection.

Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses

The present invention relates to novel cycloalkyl-hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, alzheimer's disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, syndrome x, thrombotic disorder. Compounds and methods of the invention can also be used to modulate c reactive protein or enhance bile production in a patient.
Esperion Therapeutics, Inc.

Treatment of metabolic disorders in equine animals

A sglt2 inhibitor or a pharmaceutically acceptable form thereof is provided for use in the treatment and/or prevention of a metabolic disorder of an equine animal. In particular, a sglt2 inhibitor or a pharmaceutically acceptable form thereof is provided for use in the treatment and/or prevention of insulin resistance, hyperinsulinemia, impaired glucose tolerance, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, obesity, and/or regional adiposity in an equine animal..
Boehringer Ingelheim Vetmedica Gmbh

Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling

The invention relates to the identification of new therapeutic methods for the fgf21 polypeptide or protein, or mutants, variants, and fusions thereof, for instance, in treating metabolic diseases associated defects in insulin signaling (e.g. Insulin receptor mutation disorders (insr disorders) and/or autoimmune insulin receptor disorders (type b insulin resistance)), defects in insulin production such as type 1 diabetes mellitus, mixed dyslipidemia, nonalcoholic fatty liver disease (nafld), and other metabolic disorders, and various lipodystrophies such as hiv-haart induced partial-lipodystrophy, and in reducing the mortality and morbidity of critically ill patients..
Novartis Ag

Methods for treating metabolic disorders using fgf

The method provides methods and compositions for treating metabolic disorders such as impaired glucose tolerance, elevated blood glucose, insulin resistance, dyslipidemia, obesity, and fatty liver.. .
Salk Institute For Biological Studies

Compositions and methods for treating diabetes

The present disclosure is a compound, a method of making the compound and method of using such compound preferably in the form of a dietary supplement that, when administered, is capable of treating prediabetes, diabetes, insulin resistance or metabolic syndrome. The unique combination of the composition is preferably administered orally.

Dietary compositions for reducing blood glucose levels and for weight management

The present invention provides dietary compositions comprising mulberry extract, coffee extract, bean extract, optionally, dietary fibers, and a nutraceutically acceptable carrier. The present invention further provides methods for preventing the increase in postprandial hyperglycemia and hypoglycemia, hyperinsulinemia and diseases and disorders associated therewith, including, endothelial dysfunction, inflammatory conditions, oxidative stress, hyperlipidemia, and consecutive pathologies like insulin resistance, diabetes, visceral obesity, hypertension and cardiovascular diseases..
Marmar Investment Sp. Z O.o.

Enolase 1 (eno1) compositions and uses thereof

The invention provides compositions comprising eno1 and a muscle targeting peptide, e.g, as a fusion protein, for delivery of eno1 to a muscle. The eno1 may contain one or more added cysteine residues which are covalently attached to a biocompatible polymer (e.g.
Berg Llc

Oral formulations mimetic of roux-en-y gastric bypass actions on the ileal brake; compositions, methods of treatment, diagnostics and systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hyperlipidemia, and type 2 diabetes.

In other aspects, the invention provides ileal brake hormone releasing compositions, methods of treatment, diagnostics, and related systems useful in selective control of appetite, stabilizing blood glucose and insulin levels, and treating gastrointestinal disorders in a similar manner to rygb surgery, but having at least 20% of the potency to stimulate the hormonal response of the ileal brake of humans.. .

Oral formulations mimetic of roux-en-y gastric bypass actions on the ileal brake; compositions, methods of treatment, diagnostics and systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hyperlipidemia, and t2d

In other aspects, the invention provides ileal brake hormone releasing compositions, methods of treatment, diagnostics, and related systems useful in selective control of appetite, stabilizing blood glucose and insulin levels, and treating gastrointestinal disorders in a similar manner to rygb surgery, but having at least 20% of the potency to stimulate the hormonal response of the ileal brake of humans.. .

Nutritional compositions with phospholipids

The present invention relates to a nutritional composition such as an infant formula comprising phospholipids in an amount of at least 300 mg/l. Bioactive compounds may preferably be added to the nutritional composition.
Nestec S.a.

Composition involved in regulating energy cycle, inflammation and insulin resistance dysfunctions, and use thereof particularly in cardiometabolic diseases

A composition suitable for use as a health product, including a mixture of active ingredients made up of at least: a lactoserum hydrolysate with a molecular weight between 200 and 5000 daltons, alpha-lactalbumin, at least one ampk, mapk, ppar and/or sirt1 cycle regulator, and milk calcium. The composition is particularly useful as a medical nutrition product or orally administered drug, to prevent and/or combat various diseases..
International Nutrition Research Company

Synthetic composition for treating metabolic disorders

The invention relates to a method for stabilising or reducing insulin resistance in patients having an obesity-related, metabolic disorder, the method comprising administering to the patient an effective amount of one or more human milk oligosaccharides (hmos).. .
Glycom A/s

Method to prepare hirsutella sinensis polysaccharides possessing insulin-sensitizing properties and applications thereof

The present invention provides a method to prepare polysaccharides from hirsutella sinensis. The prepared polysaccharides can reduce hyperglycemia and insulin resistance, and can therefore be used to prevent and treat type 2 diabetes and related conditions..
Chang Gung Biotechnology Corp.

Treatment of metabolic disorders in canine animals

The present invention relates to one or more sglt2 inhibitors or pharmaceutically acceptable forms thereof for use in the treatment and/or prevention of a metabolic disorder in a canine animal, preferably wherein the metabolic disorder is one or more selected from the group consisting of: ketoacidosis, pre-diabetes, insulin dependent diabetes mellitus, insulin resistance diabetes, insulin resistance, obesity, hyperglycemia, hyperglycemia induced cataract formation, impaired glucose tolerance, hyperinsulinemia, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, hepatic lipidosis, inflammation of the pancreas, metabolic disorder consequences, such as hypertension, renal dysfunction and/or muscoskeletal disorders, and/or syndrome x (metabolic syndrome), wherein preferably the development of hyperglycemia induced cataract formation is prevented or remission is achieved and/or wherein preferably the development of metabolic disorder consequences, such as hypertension, renal dysfunction and/or muscoskeletal disorders, is prevented or progression is slowed or remission is achieved.. .
Boehringer Ingelheim Vetmedica Gmbh

Novel set of fasting blood biomarkers to detect patients with impaired glucose tolerance

The present disclosure relates to methods of predicting the likelihood of a subject having impaired glucose tolerance or insulin resistance by measuring a novel set of fasting blood biomarkers.. .
True Health Diagnostics Llc

Methods for treating metabolic disorders using fgf

The method provides methods and compositions for treating metabolic disorders such as impaired glucose tolerance, elevated blood glucose, insulin resistance, dyslipidemia, obesity, and fatty liver.. .
Salk Institute For Biological Studies

Compositions for preserving insulin-producing cells and insulin production and treating diabetes

Nuclear transport modifiers such as csn50 and csn50.1, afford in vivo islet protection following a 2-day course of intense treatment in autoimmune diabetes-prone, non-obese diabetic (nod) mice, a widely used model of type 1 diabetes (t1d), which resulted in a diabetes-free state for one year without apparent toxicity and the need to use insulin. Csn50 precipitously reduces the accumulation of islet-destructive autoreactive lymphocytes while enhancing activation-induced cell death of t and b lymphocytes derived from nod mice.
Vanderbilt University

Use of melanocortins to treat insulin sensitivity

The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as insulin resistance.. .
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College

Combination of metabolic bio-energetic and nutra-epigentic regulators, nutraceutical compounds in conventional and nanotechnologies combination to revert and prevent the chronic damage accelerated cellullar senescence produced by diabetis and other degenerative chronic complex diseases

The invention relates to compounds of natural origin and their pharmaceutically acceptable and active mixture to decrease glucose, cholesterol, uric acid, and body fat the high levels, cytoprotection of damaged organs, activation of metabolism and cell proliferation. It is exemplified with the pharmaceutical composition comprising a pharmaceutically effective amount of the compounds of formulation i, and its method on in vitro and in vivo systems.

Detection of insulin resistance, diabetes, cardiovascular disease and autonomic neuropathy

A method and system for detecting insulin resistance, diabetes, cardiovascular disease and/or autonomic neuropathy in a patient is provided. The method includes measuring a photoplethysmogram (ptg) and galvanic skin response from the patient, executing a spectral analysis on the ptg, comparing values derived from the ptg and the galvanic skin response of the patient to stored clinical data, calculating a ptg cardiovascular risk score based on the comparison, comparing further derived values to predefined values that correspond to certain diseases, including insulin resistance, diabetes, cardiovascular disease and autonomic neuropathy, and displaying the ptg cardiovascular risk score and said certain diseases that correspond to said predefined values..
Medical Screening Corporation

Ketohexokinase (khk) irna compositions and methods of use thereof

The present invention relates to rnai agents, e.g., double-stranded rnai agents, targeting the ketohexokinase (khk) gene, and methods of using such rnai agents to inhibit expression of khk and methods of treating subjects having a khk-associated disorder, e.g., liver disease (e.g., fatty liver, steatohepatitis), dyslipidemia (e.g., hyperlipidemia, high ldl cholesterol, low hdl cholesterol, hypertriglyceridemia, postprandial hypertriglyceridemia), disorders of glycemic control (e.g., insulin resistance, diabetes), cardiovascular disease (e.g., hypertension, endothelial cell dysfunction), kidney disease (e.g., acute kidney disorder, tubular dysfunction, proinflammatory changes to the proximal tubules), metabolic syndrome, adipocyte dysfunction, visceral adipose deposition, obesity, hyperuricemia, gout, eating disorders, and excessive sugar craving.. .
Alnylam Pharmaceuticals, Inc.

Use of caspase-2 inhibitors to treat and prevent the metabolic syndrome

Methods and compositions for treatment of obesity, insulin resistance, hyperinsulinemia, type 2 diabetes mellitus, dyslipidemia, and nonalcoholic fatty liver disease are discloses. The methods and compositions relate to inhibition of caspase-2..
Duke University

Method for preventing and/or treating insulin resistance

Described is the use of eubacterium hallii et rel. And/or alcaligenes faecalis et rel., as well as pharmaceutical, food, or feed compositions comprising these bacteria as a medicament, in particular, for preventing and/or treating insulin resistance and/or insulin resistance-related complications such as metabolic syndrome, dyslipidemia and type 2 diabetes mellitus, as well as insulin resistance in endocrine diseases (e.g., obese subjects with type 1 diabetes mellitus, cushing's disease and lipodystrophy syndromes.
Caelus Pharmaceuticals B.v.

Uses of kappa opioid synthetic peptide amides

The invention relates to methods of use of synthetic peptide amides that are ligands of the kappa opioid receptor in the treatment and prevention of kappa opioid receptor-associated diseases and conditions; and particularly to uses of these agonists in the prophylaxis, inhibition and treatment of pain, inflammation and pruritis associated with a variety of diseases, disorders and conditions. Inflammatory conditions preventable or treatable by the methods of the invention include diseases and conditions associated with elevated levels of a proinflammatory cytokines, such as tnf-α, il-1β, il-6, mmp-1 and mmp-3.
Cara Therapeutics, Inc.

Devices and methods for treating cardiovascular and metabolic disease

Some embodiments of devices and methods described herein may, among other uses, favorably cause the activation and/or deactivation vascular baroreceptors in order to achieve a desired impact on physiological condition, including but not limited to baroreflex-regulated conditions, hypertension, hypotension, nervous system disorders, metabolic disorders, cardiovascular disease, heart failure, cardiac arrhythmia, renal disease, respiratory disease, diabetes, and insulin resistance. The devices and methods may be used in concert with each other and/or other treatments, medications, interventions, or behavioral regimens, and they may also be used in concert with devices and methods that perform or assist with any combination of the following: assessing or measuring a mammal's blood pressure; assessing, measuring, or predicting the impact of the described methods and devices on the patient's condition (including blood pressure); and/or protecting the surrounding anatomy from adverse effects..

Use of nutritional compositions having a low protein amount

The present invention relates to the use of a nutritional composition having a low amount of protein, such as less than 1.8 g/100 kcal for administration to infants of non-obese and non-overweight mothers so as to reduce the risk of developing metabolic syndrome, increased weight gain, increased fat deposition, overweight, obesity, insulin resistance, glucose intolerance or diabetes mellitus later in said infant's life.. .
Nestec S.a

Spirocyclic compounds containing spiro[indolyl-3,1'-pyrrolo[3,4-c]pyrrole] core and sulphur-containing amino acid residues

The present invention relates to spirocyclic compounds on the basis of 2-oxindole derivatives containing a spiro[indolyl-3,1′-pyrrolo[3,4-c]-pyrrole] core and biogenic sulphur-containing amino acid residues, which display a glucocorticoid-mimicking action by influencing 11β-hsd1 enzyme cortisone->cortisol conversion, or by inhibiting grs- or gitr- or mineralocorticoid receptors, or other targets, but do not interfere with steroidal haemostasis in hpa; and compositions containing same and their use for therapy as part of undifferentiated stroke therapy (in the absence of final verification of the stroke subtype) at various stages of acute ischemic stroke (ais), during the period of recovery from stroke and craniocerebral trauma, in patients with chronic cerebrovascular pathology (against a background of diabetes), in combinational therapy for alzheimer's disease and encephalopathy of various origin (discirculatory, alcoholic, infectious-toxic), and diabetes, combinational therapy for retinal degenerative eye diseases, as part of combinational therapy for metabolic syndrome (obesity, in patients suffering from cushing's syndrome, reaven metabolic syndrome (also known as syndrome x or insulin resistance syndrome) and other diseases where gcs hormones play a key role.. .

Methods for prevention and treatment of cardiometabolic syndrome and compositions used therein

Beta-cryptoxanthin compositions and methods are described for the management of cardiometabolic syndrome and associated risk factors, in a subject, in need thereof. Methods herein are directed to identifying such subject at risk of developing cardiometabolic syndrome and administering beta-cryptoxanthin composition to assess the condition of an organ.
Omniactive Health Technologies Limited

Assay for insulin-degrading enzyme (ide) inhibitors

Ide-binding probes and assays for the identification of ide-binding and ide-inhibiting compounds are provided. Pharmaceutical compositions of macrocyclic ide inhibitors are also provided, including compositions in which such ide inhibitors are combined with an additional therapeutic agent.
President And Fellows Of Harvard College

Bioeffective krill oil compositions

This invention discloses new krill oil compositions characterized by having high amounts of phospholipids, astaxanthin esters and/or omega-3 contents. The krill oils are obtained from krill meal using supercritical fluid extraction in a two stage process.
Aker Biomarine Antarctic As

Bioeffective krill oil compositions

This invention discloses new krill oil compositions characterized by having high amounts of phospholipids, astaxanthin esters and/or omega-3 contents. The krill oils are obtained from krill meal using supercritical fluid extraction in a two stage process.
Aker Biomarine Antarctic As

Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a hepatitis c virus infection

The present invention is directed to pharmaceutical compositions and methods of treatment that relate to the inhibition, resolution and/or prevention of an array of the manifestations of metabolic syndromes, including type 2 diabetes, hyperlipidemia, weight gain, obesity, insulin resistance, hypertension, atherosclerosis, fatty liver diseases and certain chronic inflammatory states that lead to these manifestations, among others. In additional aspects, the present invention relates to compositions and methods which may be used to treat, inhibit or reduce the likelihood of hepatitis viral infections, including hepatitis b and hepatitis c viral infections, as well as the secondary disease states and/or conditions which are often associated with such viral infections, including hepatic steatosis (steatohepatitis), cirrhosis, fatty liver and hepatocellular cancer, among other disease states or conditions..
Volant Holdings Gmbh

Nutritionally enhanced fraction from rice bran and lowering insulin resistance using same

Nutritionally enhanced nutraceutical hydrophilic and lipophilic rice bran fractions from rice bran are provided, as well as a method of using the same to reduce insulin resistance in animals, especially humans with pre-diabetes and type 2 diabetes or others with symptoms of metabolic syndrome. Provided in various example embodiments are mixtures of elevated levels of nutraceutical compounds, including but not limited to gamma-oryzanol, inositol, ferulic acid, tocotrienols and phytosterols and pharmaceutical and nutritional compositions thereof.

Compositions and methods for the treatment of hyperglycemia and metabolic syndrome

The invention relates to the compounds and compositions of formula i, formula ii, formula iii, formula iv, formula v, formula vi or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprises a salt of metformin and the methods for treating or preventing metabolic syndrome, prediabetes and diabetes may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection.

Method for treating or preventing nonalcoholic fatty liver disease

A method for treating or preventing non-alcoholic fatty liver disease is disclosed. By promoting the expression of six-transmembrane protein of prostate 2 (stamp2) in liver cells, the method can be useful in improving the abnormalities in lipid metabolism in the liver, and also improving insulin resistance, thereby preventing or treating a non-alcoholic fatty liver disease..
Dong-a University Research Foundation For Industry- Academy Cooperation

Methods for increasing adiponectin

In certain aspects, the present invention provides compositions and methods for increasing adiponectin in a patient in need thereof by administering an antagonist of an actriib signaling pathway. Examples of such antagonists include actriib polypeptides, anti-actriib antibodies, anti-activin a and/or b antibodies, anti-myostatin antibodies, anti-gdf3 antibodies, and anti-bmp7 antibodies.
Acceleron Pharma Inc.

Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders

The present invention is directed to a method of treating a patient suffering from the metabolic syndrome and/or related disorders including obesity, type 2 diabetes, pre-diabetes, hypertension, dyslipidemia, insulin resistance, endothelial dysfunction, pro-inflammatory state, and pro-coagulative state, and comprising the steps of (a) providing to the patient a dietary regimen that decreases overactive cns noradrenergic tone; followed by (b) providing to the patient a dietary regimen that increases dopaminergic tone while maintaining the above decreased overactive cns noradrenergic tone. The present invention is also directed to food products useful in implementing the dietary regimens..
Veroscience Llc

Inhibitors of diacylglycerol o-acyltransferase 1 (dgat-1) and uses thereof

The invention pertains to the use of fused bicyclo heterocyclic adducts of thiohydroxy pyridines or pyrimidines as diacylglycerol o-acyltransferase 1 (dgat-1) inhibitors to treat hyperlipidiemias and various diseases and disorders associated therewith. Other conditions also can be ameliorated or avoided, such as high postprandial triglycerides or diet-related hypertriglyceridemia, cardiovascular risk associated with excessive triglycerides, and insulin resistance/glucose intolerance in overweight patients, those with diabetes or other glucose metabolic disorders such as syndrome x and/or polycystic ovary disease..
Metabasis Therapeutics, Inc.

Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy

The present invention relates to methods for treating a disease associated with insulin resistance selected from a nonalcoholic fatty liver disease (nafld) and its sequelae, a lipodystrophic syndrome or a combination thereof with the selective pparγ agonist, int131 and optionally vitamin e or compositions thereof. Naflds that may be treated with methods and compositions of the present invention include, but are not limited to, simple nonalcoholic fatty liver and nonalcoholic steatohepatitis (nash).
Intekrin Therapeutics, Inc.

Composition for preventing or treating non-alcoholic liver disease or insulin resistance comprising ginsenoside f2

The present invention relates to a pharmaceutical composition, a health functional food, and a feed composition for the prevention, improvement, or treatment of non-alcoholic liver disease or insulin resistance comprising ginsenoside f2. The pharmaceutical composition according to the present invention comprising ginsenoside f2 can inhibit the adipogenesis and lipid accumulation in the liver, improve insulin sensitivity, inhibit the expression of inflammatory cytokines such as tnf-α, il-β, and il-6 in the kupffer cell, inhibit the expression of endocannabinoid synthase, thus capable of effectively preventing or treating non-alcoholic liver disease or insulin resistance..
Intelligent Synthetic Biology Center



Insulin Resistance topics:
  • Insulin Resistance
  • Metabolic Syndrome
  • C Syndrome
  • Type 2 Diabetes
  • Dyslipidemia
  • Cardiovascular Disease
  • Vascular Disease
  • Cardiovascular
  • Atherosclerosis
  • Hypertension
  • Metabolic Disorder
  • Blood Glucose
  • Fatty Liver
  • Inflammation
  • Retinopathy


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Insulin Resistance for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Insulin Resistance with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.2599

    file did exist - file did put2760

    3 - 1 - 51